MedPath

Fluid Restriction in Heart Failure Versus Liberal Fluid Uptake

Not Applicable
Completed
Conditions
Heart Failure
Interventions
Behavioral: Lifestyle advice for liberal fluid intake
Registration Number
NCT04551729
Lead Sponsor
Radboud University Medical Center
Brief Summary

Multi-centre open-label 1:1 randomized clinical trial in chronic heart failure patients on the effect of fluid restriction versus liberal fluid intake on quality of life.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
506
Inclusion Criteria
  • Diagnosis of chronic HF with NYHA class II/III according to the prevailing guidelines > 6 months prior to randomization (1)
  • Adult (age ≥ 18 years)
Read More
Exclusion Criteria
  • Reversible cause of HF (thyroid disorders, severe anemia, vitamin deficiencies)
  • Hopital admission for HF within 3 months of randomization
  • Chronic HF with NYHA class IV
  • Hyponatremia at baseline (sodium <130mmol/l)
  • Changes in HF medical therapy in last 14 days prior to randomization
  • Estimated Glomerular Filtration Rate (eGFR) of < 30ml/min/1.73 m2 at baseline
  • Scheduled cardiac surgery within 3 months of randomization
  • Recent (within 3 months) coronary intervention (PCI or CABG) or implantation of pacemaker device
  • Comorbidity for which fluid restriction is advised by a different treating physician (e.g. nephrologist)
  • Comorbidity with a life expectancy of less than 6 months
  • The treating clinician believes that participation in the domain would not be in the best interests of the patient
  • Inability to provide informed consent
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Liberal fluid intakeLifestyle advice for liberal fluid intakePatient will receive a lifestyle advice for liberal fluid intake for 3 months.
Fluid restrictionLifestyle advice for liberal fluid intakePatient will receive a lifestyle advice to adhere to fluid restriction of 1500cc/day for 3 months.
Primary Outcome Measures
NameTimeMethod
Quality of life assessed with the Kansas City Cardiomyopathy Questionnaire (KCCQ)3 months

KCCQ Overall Summary Score (OSS) (scores minimum-maximum 0-100, higher scores indicate better outcome)

Secondary Outcome Measures
NameTimeMethod
Thirst distress3 months

Thirst Distress Scale for patients with Heart Failure (scores minimum-maximum 8-40, higher scores indicate worse outcome)

Quality of life assessed with EQ-5D-5L3 months

EQ-5D-5L (First part; scores minimum-maximum 0-1. Second part; (scores minimum-maximum 0-100, higher scores indicate better outcome)

Patient reported fluid intake6 weeks

Patient reported fluid intake for 1 week in a fluid intake diary

Quality of life assessed with the Kansas City Cardiomyopathy Questionnaire (KCCQ)3 months

Proportion of patients with clinically meaningful changes in KCCQ-OSS and KCCQ-CSS (improved: ≥5 points increase; stable: \<5 points increase or decrease; declined: ≥5 points decrease)

Safety (Death, all-cause hospitalisations, iv loop diuretic treatment)6 months

Composite of death, hospitalisations and iv loop diuretic treatment

Trial Locations

Locations (8)

Hospital Group Twente

🇳🇱

Almelo, Netherlands

Radboud University Medical Center

🇳🇱

Nijmegen, Gelderland, Netherlands

Rijnstate Hospital

🇳🇱

Arnhem, Netherlands

Jeroen Bosch Ziekenhuis

🇳🇱

Den Bosch, Netherlands

Zuyderland Ziekenhuis

🇳🇱

Heerlen, Netherlands

Dijklander Ziekenhuis

🇳🇱

Hoorn, Netherlands

Maastricht University Medical Centre

🇳🇱

Maastricht, Netherlands

Bernhoven Ziekenhuis

🇳🇱

Uden, Netherlands

© Copyright 2025. All Rights Reserved by MedPath